The Journal for Nurse Practitioners
Volume 6, Issue 6 , Pages 452-463 , June 2010

Breast Cancer Follow-Up: Strategies for Successful Collaboration between Cancer Care Specialists and Primary Care Providers

  • Mary Ann Zalewski

      Affiliations

    • Mary Ann Zalewski, MSN, CRNP, AOCNP, is a nurse practitioner
    • ,
  • Susan Beikman

      Affiliations

    • Susan Beikman, MSN, CRNP, is a nurse practitioner
    • ,
  • Shannon Ferrari

      Affiliations

    • Shannon Ferrari, PA-C, MPAS, is a physician's assistant at the University of Pittsburgh Cancer Institute and Magee Women's Hospital in Pittsburgh, PA.
    • ,
  • Kathleen Slavish

      Affiliations

    • Kathleen Slavish, BA, is a research assistant in the University of Pittsburgh School of Nursing.
    • ,
  • Margaret Rosenzweig

      Affiliations

    • Margaret Rosenzweig, PhD, FNP-BC, AOCNP, is an assistant professor in the University of Pittsburgh School of Nursing.

References 

  1. American Society of Clinical Oncology  . ASCO Fall 2008 Workforce Statement . Available at: http://www.asco.org/asco/downloads/research%20policy/workforce%20page/asco%20workforce%20strategic%20plan.pdf Accessed September 10, 2009
  2. Mao JJ , Bowman MA , Stricker CT , et al.   Delivery of survivorship care by primary care physicians: The perspective of breast cancer patients . J Clin Oncol . 2009;27(6):933–938
  3. Jemal A , Siegel R , Ward E , et al.   Cancer statistics, 2008 . CA Cancer J Clin . 2008;58(2):71–96
  4. Grunfield E , Man D , Yudkin P , et al.   Routine follow up of breast cancer in primary care: Randomised trial . Br Med J . 1996;313(1):665–669
  5. Grunfeld E , Yudkin P , Adewuyl-Dalton R , et al.   Follow up in breast cancer: Quality of life unaffected by general practice follow up . Br Med J . 1995;311(1):54
  6. Grunfeld E , Levine MN , Julian JA , et al.   Randomized trial of long-term follow up for early stage breast cancer: A comparison of family physician versus specialist care . J Clin Oncol . 2006;24(1):848–855
  7. Khatcheressian JL , Wolff AC , Smith TJ , et al.   American society of clinical oncology 2006 update of the breast cancer follow up and management guidelines in the adjuvant setting . J Clin Oncol . 2006;24(1):5091–5097
  8. Loprinzini CL , Hayes D , Smith T . Doc, shouldn't we be getting some tests? . J Clin Oncol . 2000;18(1):2345–2348
  9. The GIVIO Investigators  . Impact of follow up testing on survival and health related quality of life in breast controlled patients: A multicenter randomized controlled trial . JAMA . 1994;271(1):1587–1592
  10. Rosselli Del Turco M , Palli D , Cariddi A , et al.   Intensive diagnostic follow up after treatment of primary breast cancer: A randomized trial—National Research Council Project on Breast Cancer Follow-Up . JAMA . 1994;271(1):1593–1597
  11. U.S. Preventive Task Force  . Screening for breast cancer: U.S. preventive services task force recommendation statement . Ann Intern Med . 2009;151:716–726
  12. American Cancer Society  . How is breast cancer staged? . Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_How_is_breast_cancer_staged_5.asp? sitearea= Accessed September 20, 2009
  13. McMasters KM . The eternally enigmatic axilla: Further controversy about axillary lymph nodes in breast cancer . Ann Surg Oncol . 2004;10(1):1128–1130
  14. Schwartz GF . Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: Current update . Breast J . 2004;10(1):85–88
  15. Edwards TL. Prevalence and aetiology of lymphoedema after breast cancer treatment in southern Tasmania. ANZ J Surg. 20(6):412-418.
  16. Erikson VS , Pearson ML , Ganz PA , et al.   Arm edema in breast cancer patients . J Natl Cancer Inst . 2001;93(1):96–111
  17. Goffman TE, Laronga C, Wilson L, et al. Lymphedema of the arm and breast in irradiated breast cancer patients: Risks in an era of dramatically changing axillary surgery. Breast J. 10(5): 405-411.
  18. Swenson KK , Nissen MJ , Leach JW , et al.   Case control study to evaluate predictors of lymphedema after breast cancer surgery . Oncol Nurs Forum . 2009;36(2):185–193
  19. Johansson K , Ohlsson K , Ingvar C , et al.   Factors associated with the development of arm lymphedema following cancer treating: A match pair case-control study . Lymphology . 2002;35(2):59–71
  20. Williams AF, Vadgama A, Franks PJ, et al. A randomized controlled crossover study of manual lymphatic drainage therapy in women with breast cancer-related lymphoedema. Eur J Cancer Care. 11(4): 254-261.
  21. American Cancer Society  . Possible side effects of radiation therapy . Available at: http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Side_Effects_of_Radiation_Therapy.asp Accessed September 17, 2009
  22. National Cancer Institute  . Radiation therapy side effects . Available at: http://www.cancer.gov/cancertopics/radiation-therapy-and-you/page6 Accessed September 17, 2009
  23. Hershman DL . Anthracycline cardiotoxicity after breast cancer treatment . Oncology . 2009;23(3):
  24. Pinder MC , Zhigana D , Goodwin JS , et al.   Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer . J Clin Oncol . 2007;25(25):3808–3814
  25. Pfeffer B , Tziros C , Katz R . Current concepts of anthracycline cardiotoxicity: Pathogenesis, diagnosis and prevention . Br J Cardiol . 2009;16(2):85–89
  26. Wouters KA , Kremer LC , Miller TL , Herman EH , Lipshultz SE . Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies . Br J Haematol . 2005;131:561–578
  27. Roul G , Cohen C , Lieber A . Anthracycline-induced cardiomyopathy . Press Medicale . 2009;38(6):987–994
  28. Lee J , Swain S . Peripheral neuropathy induced by microtubule-stabilizing agents . J Clin Oncol . 2006;24(10):1633–1642
  29. Dworkin RH , Backonja M , Rowbotham MC , et al.   Advances in neuropathic pain:diagnosis, mechanisms, and treatment recommendations . Arch Neurol . 2003;60(11):1524–1534
  30. Schagen SB , Van Dam FS , Muller MJ , et al.   Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma . Cancer . 1999;85(3):640–650
  31. Vardy J , Rourke S , Tannock IF . Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research . J Clin Oncol . 2007;25(17):2455–2463
  32. Grunfeld E , Dhesy-Thind S , Levine M . Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update) . CMAJ . 2005;172:1319
  33. Up To Date  . Ovarian Failure due to anticancer drugs and radiation . Available at: http://www.uptodate.com/patients/content/topic.do?topicKey=∼QTTQH1AMXyPAGQ#7 Accessed September 17, 2009
  34. Wallace WH , Thomson AB , Saran F , et al.   Predicting age of ovarian failure after radiation to a field that includes the ovaries . Int J Radiat Oncol Biol Phys . 2005;62(3):738–744
  35. World Health Organization. Research on menopause in the 1990s. Technical report Scr. 866, Geneva, Switzerland; 1996.
  36. Menard S , Fortis S , Castiglioni F , et al.   HER2 as a prognostic factor in breast cancer . Oncology . 2001;61(Suppl 2):67–72
  37. Ross JS , Fletcher JA . The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy . Stem Cells . 1998;16:413–428
  38. Emens LA , Davidson NE . Trastuzumab in breast cancer . Oncology (Williston Park) . 2004;18:1117–1128
  39. Up To Date  . Cardiotoxicity of Trastuzumab . Available at: http://www.uptodate.com/patients/content/topic.do?topicKey=∼h4anaQIBOGXLHRa&selectedTitle=5∼71&source=search_result Accessed September 17, 2009
  40. Craft BS , Hortobagyi GN , Moulder SL . Adjuvant biologic therapy for breast cancer . Cancer J . 2007;13(3):156–161
  41. American Cancer Society  . Tamoxifen cancer.org BC Facts and Figures 2007-2008 . Available at: http://www.cancer.org/downloads/STT/BCFF-Final.pdf Accessed September 22, 2009
  42. Carlson RW , Hudis CA , Pritchard KI , et al.   Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: Evolution of NCCN, ASCO, and St Gallen recommendations . J Natl Compr Canc Netw . 2006;4(10):971–979
  43. Carlson RW , Anderson BO , Burstein HJ , et al.   Breast cancer . J Natl Compr Canc Netw . 2005;3:228–289
  44. Winer EP , Hudis C , Burstein HJ , et al.   American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor positive breast cancer: status report 2004 . J Clin Oncol . 2003;21:3357–3365
  45. Goldhirsch A , Glick JH , Gelber RD , et al.   Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 . Ann Oncol . 2005;16:1569–3365
  46. Sterns V . Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms . Treat Endocrinol . 2006;5(2):83–87
  47. Kimmick GG , Lovato J , McQuellon R , et al.   Randomized, double blind, placebo-controlled, crossover study of sertaline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen . Breast J . 2006;12(2):114–122
  48. Loprinzi CL , Sloan JA , Perez EA , et al.   Phase III evaluation of fluoxetine for treatment of hot flashes . J Clin Oncol . 2002;20(6):1578–1583
  49. Loprinzi CL , Kugler JW , Sloan JA , et al.   Venlafaxine in management of hot flashes in survivors of breast cancer: A randomized controlled trial . Lancet . 2000;356(9247):2059–2063
  50. Pandya KJ , Morrow GR , Roscoe JA , et al.   Gabapentin for hot flashes in 420 women with breast cancer: A randomized double-blind placebo-controlled trial . Lancet . 2005;366(9488):818–824
  51. Loprinzi CL , Levitt R , Barton D , et al.   Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7 . J Clin Oncol . 2006;24(9):1409–1414
  52. Loprinzi CL , Kugler JW , Barton DL , et al.   Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5 . J Clin Oncol . 2007;25(3):308–312
  53. Newton KM , Buist DS , Keenan NL , et al.   Use of alternative therapies for menopause symptoms: results of a population-based survey . Obstet Gynecol . 2002;100:18
  54. Keenan NL , Mark S , Fugh-Berman A , et al.   Severity of menopausal symptoms and use of both conventional and complementary/alternative therapies . Menopause . 2003;10:507
  55. Barton DL , Loprinzi CL , Quella SK , et al.   Prospective evaluation of vitamin E for hot flashes in breast cancer survivors . J Clin Oncol . 1998;16(2):495–500
  56. Elkins G , Marcus J , Sterns V , et al.   Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors . Psychooncology . 2007;16(5):487–492
  57. Carpenter JS , Wells N , Lambert B , et al.   A pilot study of magnetic therapy for hot flashes after breast cancer . Cancer Nursing . 2002;25(2):104–109
  58. Deng G , Vickers A , Yeung S , et al.   Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients . J Clin Oncol . 2007;23(35):5584–5590
  59. Nedstrand E , Wijma K , Wyon Y , et al.   Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: A preliminary study . Climacteric . 2005;8(3):243–250
  60. Fisher B , Costantino JP , Wickerham DL , et al.   Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study . J Natl Cancer Inst . 1998;90:1371–1388
  61. National Comprehensive Cancer Network  , American Cancer Society  . Breast Cancer Treatment Guidelines for Patients . Atlanta, GA: American Cancer Society; 2006; version VIII
  62. National Comprehensive Cancer Network  . Breast cancer clinical practice guidelines in oncology, version 2, 2006 . Available at: http://www.nccn.org/professionals/physicians_gls/PDF/breast.pdf Accessed September 22, 2009
  63. Baum M , Budzar AU , Cuzick J , et al.   Anastrolzole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: First results of the ATAC randomized trial . Lancet . 2002;359:2131–2139
  64. Goss PE , Ingle JN , Martino S , et al.   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer . N Engl J Med . 2003;349:1793–1802
  65. Howell A , Cuzick J , Baum M , et al.   Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer . Lancet . 2005;265:60–62
  66. Thurlimann B . Hormonal treatment of breast cancer: New developments . Oncology . 1998;55:501–507
  67. Coombes RC , Hall E , Gibson LJ , et al.   A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer . N Engl J Med . 2004;350:1081–1092
  68. Goss PE , Ingle JN , Martino S , et al.   Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated finding from NCIC CTG MA 17 . J Natl Cancer Inst . 2005;97:1262–1271
  69. Baum M , Buzdar A , Cuzick J , et al.   Anastrozole alone or in combination with tamoxifen versus tamoxifen alone or for adjuvant treatment of post-menopausal women with early-stage breast cancer: Results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses . Cancer . 2003;98:1802–1810
  70. Collaborative Group on Hormonal Factors in Breast Cancer . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . Lancet . 2005;365(9472):1687–1717
  71. Bonneterre J , Thrulimann B , Robertson JF , et al.   Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study . J Clin Oncol . 2000;18:3748–3757
  72. Perez EA . Safty profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer . Ann Oncol . 2007;18(Suppl. 8):26–35
  73. Theriault RL , Biermann JS , Brown E , et al.   NCCN Task Force Report: Bone Health and Cancer Care . J Natl Compr Canc Netw . 2006;S1–S20
  74. Thorne C . Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy . Current Opinion in Oncology . 2007;19(Suppl 1):S19–S28
  75. Brown J , Josse R . Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada . CMAJ . 2002;167(Suppl 10):S1–S34
  76. Raisz LG . Clinical practice: Screening for osteoporosis . N Engl J Med . 2005;353:164–171
  77. Osowski M . Spinal cord compression: An obstructive oncologic emergency . Medsc Top Adv Pract Nurs . 2002;2(4):1–8
  78. Flaherty AM . Spinal cord compression . In:  Yarbro CH ,  Frogge MH ,  Goodman M ,  Groenwald SL editor. Cancer nursing: Principles and practice . 5th ed.. Sudbury, MA: Jones and Bartlett Publishers; 2000;p. 887–899
  79. Otto SE . Oncology nursing . 5th ed.. St. Louis: Mosby-Yearbook, Inc.; 2007;
  80. Ratliff JK , Cooper PR . Metastatic spine tumors . South Med J . 2004;97(3):246–253
  81. Gebaur GP , Farjoodi P , Sciubba DM , et al.   Magnetic resonance imaging of spine tumors: Classification, differential diagnosis, and spectrum of disease . J Bone Joint Surg . 2008;90:146–162
  82. Lin N , Winer EP . Brain metastases: The HER2 paradigm . Clin Cancer Res . 2007;13(6):1648–1655
  83. Gori S , Rimondini S , DeAngelis V , et al.   Central nervous system metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors . Oncologist . 2007;12(7):766–773
  84. Hicks DG , Short SM , Prescott NL , et al.   Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR . Am J Surg Pathol . 2006;30(9):1097–1104
  85. Diaz-Guzman E , Budev M . Accuracy of the physical examination evaluating pleural effusion . Cleve Clin J Med . 2008;
  86. Weitzen R , Tichler T , Kauffman B , et al.   Body weight, nutritional factors and physical activity—their influence on prognosis after breast cancer diagnosis . Harefuah . 2006;145(11):820–825
  87. American Cancer Society  . Breast cancer facts and figures . Available at: http://www.cancer.org/downloads/STT/500809web.pdf 2009; Accessed September 9, 2009
  88. Irwin ML , McTiernan A , Baumgartner RN , et al.   Changes in body fat and weight after breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors . J Clin Oncol . 2005;23(4):774–782
  89. McTiernanan A . Obesity and cancer: the risks, science, and potential management strategies . Oncology . 2005;19(7):871–881
  90. Sternfeld B , Weltzien E , Quesenberry CP , et al.   Physical activity and risk of recurrence and mortality in breast cancer survivors: findings from the LACE study . Cancer Epidemiol . 2009;18(1):87–95
  91. Blackburn GL , Wang KA . Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS) . Am J Clin Nutr . 2007;86(3):s878–s881
  92. Chlebowski RT , Blackburn GL , Thomson CA . Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study . J Natl Cancer Inst . 2006;98(24):1767–1776
  93. Balard-Barbash R , Hunsberger S , Alciati MH , et al.   Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations . J Natl Cancer Inst . 2009;101(9):630–643
  94. Ganz P . Quality of life across the continuum of breast cancer care . The Breast J . 2008;6(5):324–330
  95. Turner J , Kelly B , Swanson C , et al.   Psychosocial impact of newly diagnosed advanced breast cancer . Psychooncology . 2005;14(5):396–407

 In compliance with national ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.

PII: S1555-4155(10)00006-1

doi: 10.1016/j.nurpra.2010.01.003

The Journal for Nurse Practitioners
Volume 6, Issue 6 , Pages 452-463 , June 2010

Article Tools